Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Registration Number
- NCT00154414
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This trial is conducted in Japan. The aim of this research trial is to evaluate the effect of treatment with liraglutide or placebo on blood glucose control after 14 weeks in Japanese subjects with type 2 diabetes. Liraglutide or placebo is administered by injection once daily in the evening. The trial is a multi-national trial with treatment concealed to participating subjects, investigators and the sponsor. Treatment allocation is random with equal chance of being assigned to each group.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 226
Inclusion Criteria
- Subjects diagnosed with type 2 diabetes and treated with diet therapy with or without single oral drug therapy
- 7.0 % =< HbA1c < 10.0 %
- Body Mass Index (BMI) < 30.0 kg/m^2
Exclusion Criteria
- Subjects treated with thiazolidinediones or insulin
- Subjects with any serious medical conditions
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method HbA1c after 14 weeks treatment
- Secondary Outcome Measures
Name Time Method Body weight after 14 weeks. Glycaemic control parameters (fasting plasma glucose, post prandial plasma glucose) after 14-week treatment Safety and tolerability
Trial Locations
- Locations (1)
Novo Nordisk Investigational Site
🇯🇵Tokyo, Japan